YES1 and non-small cell lung carcinoma: Garmendia and colleagues also showed that in vivo, dasatinib treatment decreased tumor volume in high Yes-expressing NSCLC cell lines and patient-derived xenograft tumors, whereas low Yes-expressing NSCLC cell lines and patient-derived xenograft tumors were more resistant to dasatinib treatment.